-Pierre Fabre Laboratories anuncia la concesión de la autorización de comercialización europea para OBGEMSA™ (vibegron) en el tratamiento de la vejiga hiperactiva CASTRES, Francia, 28 de junio de 2024 /PRNewswire/ — La Comisión Europea (CE) ha autorizado la comercialización de OBGEMSA™…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.